Plasma Level of miRNA-7, miRNA-409 and miRNA-93 as Potential Biomarkers for Colorectal Cancer

Document Type: Research Article


1 Department of Biology, Faculty of Sciences, Payame Noor University, Tehran, Iran

2 Bonab Islamic Azad University, Bonab, Iran


Colorectal cancer (CRC) is among deadliest cancers all over the world. Regarding its high mortality, some researches have focused to discover new applicable diagnosis methods. In this regard, circulatory miRNAs has been received huge consideration as promising biomarkers for early detection of CRC. The study aimed to evaluate the expression level of miRNA-7, miRNA-93, and miRNA-409 in plasma of CRC patients compared to healthy controls. According to the results, miRNA-7 and miRNA-409 were significantly upregulated in plasma of CRC patients (p< 0.05) while miRNA-93 was insignificantly elevated in CRC patients (p> 0.05). Therefore, it seems that upregulation of miRNA-7, miRNA-93, and miRNA-409 is involved in CRC carcinogenesis. Additionally, miRNA-7 and miRNA-409 could be considered as novel potential biomarkers for CRC.


Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H, Allison RR. 2013. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10(3): 93-113.

Ahmed FE, Amed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Allison RR. 2012. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics 9(4): 179-192.

Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F. 2015. Colorectal cancer prevention in Europe: burden of disease and status of screening programs. Prev Med 62: 132-141.

Aminisepehr F, Babaei E, Hosseinpour Feizi MA. 2018. Study of the Expression of miR-4270 in Plasma of Patients with Breast Invasive Ductal Carcinoma. J Genet Resour 4(2): 85-89.

Bai R, Weng C, Dong H, Li S, Chen G, Xu Z. 2015. MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting GAB1 expression. Int J Cancer 137(10): 2310-2322.

Cao GH, Sun XL, Wu F, Chen WF, Li JQ, Hu WC. 2016.  Low expression of miR-409-3p is a prognostic marker for breast cancer. Eur Rev Med Pharmacol Sci 20(18): 3825-3829.

Catela Ivkovic T, Voss G, Cornella H, Ceder Y. 2017. microRNAs as cancer therapeutics: A step closer to clinical application. Cancer Lett 407: 113-122.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X,  Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10): 997-1006.

Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. 2013a. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132(7): 1602-1612.

Cuk K, Zucknick M, Madhavan D, Schott S, Golatta M, Heil J, Marme F, Turchinovich A, Sinn P, Sohn C, Junkermann H, Schneeweiss A, Burwinkel B. 2013b. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS One 8(10): e76729.

Damandan M, Moradpour Hesari R. 2016. The Association of pre-mir-196a2 T/C Polymorphism and Risk of Gastric Cancer in Ardabil, Iran. J Genet Resour 2(1): 48-51.

Djuranovic S, Nahvi A, Green R. 2012. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 336(6078): 237-240.

Dong Y, Yu J, Ng SS. 2014. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res 6: 405-422.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5): E359-386.

Guan H, Li W, Li Y, Wang J, Li Y, Tang Y, Lu S. 2017. MicroRNA-93 promotes proliferation and metastasis of gastric cancer via targeting TIMP2. PLoS One 12(12): e0189490.

Horsham JL, Kalinowski FC, Epis MR, Ganda C, Brown RA, Leedman PJ. 2015. Clinical Potential of microRNA-7 in Cancer. J Clin Med 4(9): 1668-1687.

Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. 2008. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3(11): e3694.

Jonas S, Izaurralde E. 2015. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 16(7): 421-433.

Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. 2014. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res 20(17): 4636-4646.

Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW. 2015.  Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene 34(21): 2690-2699.

Lu P, Wang F, Wu J, Wang C, Yan J, Li ZL, Song JX, Wang JJ. 2017. Elevated Serum miR-7, miR-9, miR-122, and miR-141 Are Noninvasive Biomarkers of Acute Pancreatitis. Dis Markers 2017: 7293459.

Luo X, Stock C, Burwinkel B, Brenner H. 2013. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One 8(5): e62880.

Masuda T, Hayashi N, Kuroda Y, Ito S, Eguchi H, Mimori K. 2017. MicroRNAs as Biomarkers in Colorectal Cancer. Cancers (Basel) 9(9).

Meng X, Joosse SA, Muller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H. 2015. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer 113(9): 1358-1366.

Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1(12): 882-891.

Moles R. 2017. MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment. Microrna 6(2): 102-109.

Nakagawa Y, Akao Y, Taniguchi K, Kamatani A, Tahara T, Kamano T, Nakano N, Komura N, Ikuno H, Ohmori T, Jodai Y, Miyata M, Nagasaka M, Shibata T, Ohmiya N, Hirata I. 2015. Relationship between expression of onco-related miRNAs and the endoscopic appearance of colorectal tumors. Int J Mol Sci 16(1): 1526-1543.

Ng SC, Wong SH. 2013. Colorectal cancer screening in Asia. Br Med Bull 105: 29-42.

Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW. 2013. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73(4): 346-354.

Pawa N, Arulampalam T, Norton JD. 2011. Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol 8(12): 711-722.

Rao Q, Shen Q, Zhou H, Peng Y, Li J, Lin Z. 2012. Aberrant microRNA expression in human cervical carcinomas. Med Oncol 29(2): 1242-1248.

Reddy KB. 2015. MicroRNA (miRNA) in cancer. Cancer Cell Int 15: 38.

Ren A, Dong Y, Tsoi H, Yu J. 2015. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci 16(2): 2810-2823.

Scartozzi M, Giampieri R, Del Prete M, Faloppi L, Bianconi M, Vincenzi B, Tonini G, Santini D, Cascinu S. 2014. Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opin Pharmacother 15(1): 143-150.

Siegel R, Desantis C, Jemal A. 2014. Colorectal cancer statistics, 2014. CA Cancer J Clin 64(2): 104-117.

Sovich JL, Sartor Z, Misra S. 2015.  Developments in Screening Tests and Strategies for Colorectal Cancer. Biomed Res Int 2015: 326728.

Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M. 2014. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol 20(33): 11727-11735.

Sung JJ, Ng SC, Chan FK, Chiu HM, Kim HS, Matsuda T, Ng SS, Lau JY, Zheng S, Adler S, Reddy N, Yeoh KG, Tsoi KK, Ching JY, Kuipers EJ, Rabeneck L, Young GP, Steele RJ, Lieberman D, Goh KL. 2014. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 64(1): 121-132.

Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T, Kuwano H. 2015. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis 36(3): 338-345.

Tafrihi M., Hasheminasab E. 2019. MiRNAs: Biology, Biogenesis, their Web-based Tools, and Databases. MicroRNA 8(1): 4-27.

Turchinovich A, Weiz L, Langheinz A, Burwinkel B. 2011. Characterization of extracellular circulating microRNA. Nucleic Acids Res 39(16): 7223-7233.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6): 654-659.

Vickers KC, Remaley AT. 2012. Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 23(2): 91-97.

Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. 2012. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 7(7): e41561.

Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, Wang JY. 2016. Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients. J Transl Med 14(1): 108.

Yu H, Xing H, Han W, Wang Y, Qi T, Song C, Xu Z, Li H, Huang Y. 2017. MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1. Tumour Biol 39(5): 1010428317701647.

Zare M, Bastami M, Solali S, Alivand MR. 2018. Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: Diagnosis and therapeutic implications. J Cell Physiol 233(5): 3729-3744.

Zedan AH, Hansen TF, Assenholt J, Pleckaitis M, Madsen JS, Osther PJS. 2018. microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer. Tumour Biol 40(5): 1010428318775864.

Zhang G, Liu Z, Xu H, Yang Q. 2016. miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1. Biochem Biophys Res Commun 469(2): 189-195.